Lord, Abbett & Co
CGON icon

Lord, Abbett & Co’s CG Oncology CGON Stock Holding History

Lord, Abbett & Co’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.9M Buy
364,539
+24,342
+7% +$1.59M 0.07% 273
2026
Q1 		$23M Buy
340,197
+214,561
+171% +$12.2M 0.08% 256
2025
Q4 		$5.22M Buy
+125,636
New +$5.2M 0.02% 458

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Lord, Abbett & Co's CGON Position: Q2 2026 in Review

Lord, Abbett & Co increased its CG Oncology (CGON) stake by 7.2% in Q2 2026, buying an estimated $1.59M and bringing the position to 364,539 shares worth $25.9M. The position accounts for 0.07% of the portfolio, ranked #273.

Lord, Abbett & Co first reported a position in CGON in Q4 2025 and has held it in 3 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Lord, Abbett & Co held 364,539 shares of CG Oncology worth $25.9M as of Q2 2026.
  • Lord, Abbett & Co bought 24,342 CG Oncology shares in Q2 2026, an estimated $1.59M.
  • CG Oncology made up 0.07% of Lord, Abbett & Co's portfolio in Q2 2026, its #273 holding.
  • Lord, Abbett & Co first reported a position in CG Oncology in Q4 2025 and has held it in 3 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.